Intensive Dose Ifosfamide and Etoposide with G-CSF for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma

References

• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1008
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Rodriguez MA, Cabanilla FC, Hagemeister FB, et al. A phase II trial of Mesna/Ifosfamide, mitoxanthrone and etoposide for refractory lymphomas. Ann Oncol 1995; 6: 609–611
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP An effective chemotherapy regimen in refractory and relapsing lymphoma. A 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous, bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Indovina A, Majolino I, Buscemi F, et al. Engraftment kinetics and long term stability of hematopoiesis following autografting of peripheral blood stem cells. Haemotologica 1995; 80: 115–122
   PubMedGoogle Scholar
• Langenmayer I, Weaver C, Buckner CD, et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241–246
   PubMed Web of Science ®Google Scholar
• To LB, Roberts MM, Haylock DN, et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplantion 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• van der Wall E, Richel DJ, Hollkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994; 5: 795–802
   PubMed Web of Science ®Google Scholar
• Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myelobfative chemotherapy. Blood 1995; 86: 3961–3969
   PubMed Web of Science ®Google Scholar
• Lickliter JD, Begley CG, Boyd AW, et al. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilize large numbers of peripheral blood progenitor cells in treated patients. Leuk Lymphoma 1994; 15: 91–97
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophos-phamide (4 or 7 gm/m2) and granulocyte colony stimulation factor in patients with multiple myeloma. Bone Marrow Transplantation 1996; 17: 691–697
   PubMed Web of Science ®Google Scholar
• Haynes AP, Hunter A, McQuaker G, et al. Engraftment characteristics of peripheral blood stem cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplantation 1995; 16: 359–363
   PubMed Web of Science ®Google Scholar
• Olivieri A, Offidani M, Ciniero L, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplantation 1995; 16: 85–93
   PubMed Web of Science ®Google Scholar
• McQuaker IG, Haynes AP, Stainer C, et al. Stem cell mobilization in resistant or relapse lymphoma: Superior yield of progenitor cells following a salvage regimen comprising ifosfamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Heamatol 1997; 98: 228–233
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Rossi A., Viero P, et al. Beam chemotherapy and autologous hernatopoietic progetlitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol 1997; 99: 379–385
   PubMed Web of Science ®Google Scholar
• Caballero MD, Rubio V, Heras I, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R., McMillan A, et al. Beam chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's Lymphoma. J Clin Oncol 1995; 13: 588–595
   PubMed Web of Science ®Google Scholar
• Hum SD, Hester J, Spitzer G, et al. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulo-cyte-macrophage colony-stimulation factor after high-dose cyclophosphamide, etoposide, and cisplatin. Blood 1992; 79: 3388–3393
   PubMed Web of Science ®Google Scholar
• Huan SD, Yan JC, Dunphy FR, et al. Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide. and cisplatin. J Clin Oncol 1991; 9: 1609–1617
   PubMed Web of Science ®Google Scholar
• Neidhart JA, Kohler W, Stidley C, et al. Phase I study of repeated cycles of highdose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990; 8: 1728–1738
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD, Division of cancer treatment. National Cancer Institute. 1988
   Google Scholar
• Antman KH, Montella D, Rosenbaum C, et al. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 1985; 69: 499–504
   PubMedGoogle Scholar
• Antman KH, Elias A, Ryan L, et al. Ifosfamide and mesna: Response and toxicity at standard and high dose schedules. Semin Oncol 1990; 17: 68–73
   PubMed Web of Science ®Google Scholar
• Coiffier B. Ifosfamide in the treatment of lymphoma. Semin Oncol 1996; 23: 2–7, (suppl. 7)
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Ifosfamide combinations in lymphoma. Semin Oncol 1990; 17: 58–62, (suppl 4).
   PubMed Web of Science ®Google Scholar
• Vose JM. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Sem Oncol 1996; 23: 33–37
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Legha SS, Patel SR, et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M. Anderson experience. Cancer Chem Pharmacol 1993; 31: 174–179, D;:(suppl 2).
   PubMed Web of Science ®Google Scholar
• Baars JW, Holtkamp MJ, Nooyew WJ, et al. Mobilization of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgastrim) in patients with malignant lymphomas or solid tumors. Anti-cancer Res 1996; 16: 3089–3095
   PubMed Web of Science ®Google Scholar
• Haas R., Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
   PubMed Web of Science ®Google Scholar
• Dreger P, Moss M, Petersen B, et al. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970–3978
   PubMed Web of Science ®Google Scholar